ACT CAPITAL ADVISORS

Available for Acquisition: #201407

Medical & Surgical Equipment Manufacturer

Company Overview

ACT Capital is pleased to offer for acquisition a highly profitable medical technology company. The Company's core business is advancing the art of aesthetic, pain management, and regenerative injectables. It designs, patents, and manufactures proprietary FDA 361 and 510K compliant and approved medical products for the harvesting, processing, and deployment of autologous soft tissue. Over 300 doctors are using the products in the fields of aesthetic and cosmetic surgery applications, regenerative medicine, pain management, anti-aging, and wound care procedures.

Investment Highlights

- **Proven Product.** The Company produces innovative technologies that can transfer the patient's own adipose tissue under local anesthesia, with little to no recovery time. It provides the full stack of medical products for varying types for plastic surgery and orthopedic procedures.
- **Intellectual Property.** The Company is an intellectual property think tank, development company, and distributor. From concept to validation, then manufacturing, the Company is meticulous in how and why it develops the products it does. Most products are either patented, copyrighted or FDA approved.
- **Clinical Support.** The Company has a team of physician advisors to provide support to physicians long after the initial sale of the products to ensure favorable outcomes.
- **Growth Opportunities.** The Company continues to grow with the 510K approval opening the insurance pay market, a new laser sculpting product line, new patented micro cannula products, new cannister systems, and a multi-year engineering design & product provisioning contract moving into product order phase in late 2025. It also has new distributors in Japan and Canada and more U.S. sales reps.

Innovative New Products

- **2017:** 1st Fully Reusable and Disposable Plastic Systems
- **2018:** 1st Fat Grafting Kit to Transfer Patients Own Adipose Tissue Under Local Aesthetic
- **2020:** Patent Awarded for Super G Micro Cannula – Online Store Launched
- **2021:** National Rollout of Custom Designed Product to Multi-State Body Contouring Co. – Launched Service/Mtce Dept.
- **2022:** Launched 2 New Products
- **2023:** New Product Received 510K Approval for Adipose Tissue Transfer for Medical (Orthopedic) Procedures
- **2024:** Full FDA 510K Approval for Custom Product for National Medical Clinic Operator

Available for Acquisition: #201407
Medical & Surgical Equipment Manufacturer

Summary Financial Information

	2020	2021	2022	2023	2024
Sales	$2.35M	$5.00M	$4.31M	$3.58M	$3.62M
Gross Margin	$1.57M	$3.57M	$2.19M	$1.82M	$3.15M
Adj. EBITDA	$0.72M	$2.20M	$0.81M	$0.51M	$0.92M

Contact Information

For more information, please contact:

ACT Capital Advisors, LLC
7525 SE 24th Street, Suite 630
Mercer Island, WA 98040

Interested parties should execute the attached Non-Disclosure Agreement (NDA) and return to ACT Capital Advisors with a written request to receive the Confidential Information Memorandum (CIM).
NDAs and CIM requests should be submitted to: Madison Brown

Kevin Outcalt
Managing Director
koutcalt@actcapitaladvisors.com
Phone: (925) 785-9486

Jeff Zanardi
Managing Director
jzanardi@actcapitaladvisors.com
Phone: (408) 832-7241